Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Cancer. 2024 Jan;130(2):287-299. doi: 10.1002/cncr.35021. Epub 2023 Oct 6.
The authors assessed the clinical utility of patient-reported symptom monitoring in the setting of newly diagnosed chronic myeloid leukemia (CML). The primary objective was to evaluate adherence to therapy.
The authors conducted an international prospective study that included patients with newly diagnosed, chronic-phase CML. Before clinical consultation, patients were provided a tablet computer to self-rate their symptoms, and the results were available in real time to each physician during the patient's visit. Adherence was assessed by pill count and with a validated self-reported questionnaire. The proportions of optimal responders at 3 and 6 months were assessed according to the European LeukemiaNet criteria.
Between July 2020 and August 2021, 94 patients with a median age of 57 years were enrolled. Pill count adherence analysis indicated that 86 of 93 evaluable patients (92.5%) took at least 90% of prescribed tyrosine kinase inhibitor therapy during the 6-month observation period. The online platform was well accepted by patients and physicians. An optimal response was achieved by 69 of 79 patients (87.3%) at 3 months and by 61 of 81 patients (75.3%) at 6 months.
Patient-reported symptom monitoring from the beginning of therapy in patients with CML may be critical to improve adherence to therapy and early molecular response rates (ClinicalTrials.gov identifier NCT04384848).
作者评估了在新诊断的慢性髓性白血病（CML）背景下患者报告症状监测的临床实用性。主要目的是评估治疗依从性。
作者进行了一项国际前瞻性研究，纳入了新诊断的慢性期 CML 患者。在临床咨询之前，患者被提供了一个平板电脑来自我评估他们的症状，并且在患者就诊期间，结果实时提供给每位医生。通过药片计数和经过验证的自我报告问卷来评估依从性。根据欧洲白血病网络标准评估了 3 个月和 6 个月时最佳应答者的比例。
在 2020 年 7 月至 2021 年 8 月期间，共纳入了 94 名中位年龄为 57 岁的患者。药片计数依从性分析表明，在 6 个月的观察期内，93 名可评估患者中有 86 名（92.5%）至少服用了 90%的规定酪氨酸激酶抑制剂治疗。在线平台得到了患者和医生的广泛认可。在 3 个月时有 69/79 名（87.3%）患者达到了最佳应答，在 6 个月时有 61/81 名（75.3%）患者达到了最佳应答。
从 CML 患者开始治疗时进行患者报告症状监测可能对提高治疗依从性和早期分子反应率至关重要（ClinicalTrials.gov 标识符：NCT04384848）。
